This case-control study evaluates the estimated vaccine effectiveness against infection changes over time to help inform public health policy and clinical practices.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696565 | PMC |
| http://dx.doi.org/10.1001/jamanetworkopen.2021.43346 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acute respiratory failure in influenza as a cause of out-of-hospital cardiac arrest.
Klin Mikrobiol Infekc Lek
June 2024
Clinic of Infectious Diseases and Travel Medicine, University Hospital Pilsen, Czech Republic, e-mail:
Influenza is an infectious disease caused by influenza A, B, and sometimes C viruses. The disease is preventable in all age groups thanks to annual seasonal vaccination. Population groups at high risk of severe illness with complications include seniors, pregnant women, and young children.
View Article and Find Full Text PDFHigh Mortality Due to Pneumococcal Meningitis in Children With Sickle Cell Disease: A French Multicenter Observational Study From 2001 to 2021.
Pediatr Infect Dis J
March 2025
From the Pediatrics Department, Jean Verdier Hospital, Assistance Publique-Hôpitaux de Paris, Bondy, France.
Background: Sickle cell disease (SCD) predisposes children to bacterial infections, particularly invasive pneumococcal disease. Pneumococcal immunization associated with antibiotic prophylaxis reduced the incidence of invasive pneumococcal disease in these patients. However, the risk remains higher than in the general population.
View Article and Find Full Text PDFComparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Adults with Underlying Medical Conditions: Systematic Literature Review and Pairwise Meta-Analysis Using GRADE.
Adv Ther
March 2025
Moderna, Inc., Cambridge, MA, USA.
Introduction: This systematic literature review and pairwise meta-analysis evaluated the comparative effectiveness of mRNA-1273 versus BNT162b2 in patients with at least one underlying medical condition at high risk for severe COVID-19.
Methods: MEDLINE, Embase, and Cochrane databases were searched for relevant articles from January 1, 2019 to February 9, 2024. Studies reporting effectiveness data from at least two doses of mRNA-1273 and BNT162b2 vaccination in adults with medical conditions at high risk of developing severe COVID-19 according to the US Centers for Disease Control and Prevention were included.
Seroprevalence of SARS-CoV-2 IgG antibodies in children seeking medical care in Seattle, WA June 2020 to December 2022.
Microbiol Spectr
March 2025
Seattle Children's Research Institute, Seattle, Washington, USA.
Seroprevalence studies play an important role in estimating the number of children infected with SARS-CoV-2. We report SARS-CoV-2 seroprevalence in children seeking medical care for any reason at a free-standing pediatric hospital in Seattle, WA over a 2.5-year period and four distinct pandemic waves.
View Article and Find Full Text PDFCost-Effectiveness of Nirmatrelvir/Ritonavir in COVID-19 Patients at High-Risk for Progression in Spain.
J Med Virol
March 2025
Pfizer S.L.U, Madrid, Spain.
The objective was to estimate the cost-effectiveness of nirmatrelvir/ritonavir (NMV/r) in treating adults with COVID-19 at high-risk of developing severe COVID-19 who do not require supplemental oxygen, compared to no treatment, from the Spanish National Health System (NHS) perspective. A decision-tree for the first year followed by a two-state Markov model with annual cycles for a lifetime horizon was developed. A cohort of 1000 high-risk, symptomatic COVID-19 patients entered the decision-tree for each comparator, divided into hospitalized patients, considering their level of care, and outpatients, for whom only symptom duration was considered.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!